CanSino Biologics has decided to move its COVID-19 vaccine candidate, Ad5-nCoV, into a phase 2 trial in China.

The double-blind, placebo-controlled study in 500 healthy patients will be done along with the Academy of Military Medical Sciences’ Institute of Biotechnology.

The drugmaker decided to advance to a phase 2 trial based on preliminary safety data from its phase 1 trial that began on March 18.